Regeneron Pharmaceuticals (REGN) Competitors $550.52 -14.11 (-2.50%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REGN vs. AMGN, GILD, MRNA, NTLA, VIR, VRTX, ABBV, LLY, MRK, and PFEShould you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector. Regeneron Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Moderna Intellia Therapeutics Vir Biotechnology Vertex Pharmaceuticals AbbVie Eli Lilly and Company Merck & Co., Inc. Pfizer Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Does the media refer more to REGN or AMGN? In the previous week, Amgen had 24 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 65 mentions for Amgen and 41 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.12 beat Amgen's score of 1.08 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 24 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 44 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, REGN or AMGN? Regeneron Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Is REGN or AMGN a better dividend stock? Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Regeneron Pharmaceuticals pays out 8.9% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Do analysts prefer REGN or AMGN? Regeneron Pharmaceuticals presently has a consensus price target of $817.46, indicating a potential upside of 50.47%. Amgen has a consensus price target of $309.42, indicating a potential upside of 5.86%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 7 Hold rating(s) 18 Buy rating(s) 3 Strong Buy rating(s) 2.79Amgen 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35 Which has stronger valuation & earnings, REGN or AMGN? Regeneron Pharmaceuticals has higher earnings, but lower revenue than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.20B4.05$4.41B$39.6813.69Amgen$33.42B4.71$4.09B$12.2323.90 Do institutionals and insiders believe in REGN or AMGN? 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is REGN or AMGN more profitable? Regeneron Pharmaceuticals has a net margin of 31.37% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Regeneron Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.37% 15.06% 11.77% Amgen 18.96%174.71%13.12% SummaryRegeneron Pharmaceuticals beats Amgen on 11 of the 20 factors compared between the two stocks. Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REGN vs. The Competition Export to ExcelMetricRegeneron PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.77B$3.33B$6.05B$10.24BDividend Yield0.62%2.31%5.73%4.78%P/E Ratio13.7422.2586.3326.55Price / Sales4.05417.09600.12186.81Price / Cash12.3544.9825.7330.17Price / Book2.0210.2112.866.52Net Income$4.41B-$52.40M$3.31B$276.31M7 Day Performance-7.21%0.20%-0.74%-2.92%1 Month Performance-2.99%13.49%8.31%4.14%1 Year Performance-46.51%27.29%79.14%30.13% Regeneron Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REGNRegeneron Pharmaceuticals4.7323 of 5 stars$550.52-2.5%$817.46+48.5%-44.4%$58.24B$14.20B13.8515,106Positive NewsAnalyst ForecastAnalyst RevisionGap DownAMGNAmgen4.5512 of 5 stars$296.54+0.3%$309.42+4.3%-11.6%$159.45B$33.42B24.2228,000Positive NewsAnalyst DowngradeAnalyst RevisionGILDGilead Sciences4.8843 of 5 stars$116.95+0.1%$117.67+0.6%+37.9%$145.10B$28.75B23.3017,600Positive NewsAnalyst RevisionMRNAModerna4.221 of 5 stars$29.39+7.5%$41.81+42.3%-54.0%$11.39B$3.24B-3.875,800Analyst ForecastNTLAIntellia Therapeutics3.9849 of 5 stars$25.24+23.5%$27.95+10.7%+32.0%$2.74B$57.88M-5.44600Gap UpVIRVir Biotechnology3.2892 of 5 stars$6.05+6.9%$17.30+186.0%-23.6%$830.88M$74.21M-1.50580VRTXVertex Pharmaceuticals4.7789 of 5 stars$416.13+1.4%$493.81+18.7%-15.3%$106.68B$11.02B29.746,100Positive NewsAnalyst ForecastAnalyst RevisionABBVAbbVie4.5718 of 5 stars$231.96-0.4%$229.14-1.2%+18.9%$409.53B$56.33B110.3955,000Positive NewsAnalyst ForecastAnalyst RevisionLLYEli Lilly and Company4.9913 of 5 stars$851.86+1.0%$943.00+10.7%-10.6%$806.06B$45.04B55.6647,000Positive NewsAnalyst ForecastAnalyst RevisionMRKMerck & Co., Inc.4.9927 of 5 stars$87.00-0.7%$104.31+19.9%-21.6%$217.32B$64.17B13.4175,000Positive NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.9527 of 5 stars$25.91-1.4%$28.41+9.6%-14.9%$147.39B$63.63B13.7981,000Positive NewsDividend AnnouncementAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vir Biotechnology Alternatives Vertex Pharmaceuticals Alternatives AbbVie Alternatives Eli Lilly and Company Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REGN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
